Thomas B Neff Net Worth

The estimated Net Worth of Thomas B Neff is at least $153 Milion dollars as of 21 August 2019. Thomas Neff owns over 39,636 units of FibroGen Inc stock worth over $17,695 and over the last 10 years Thomas sold FGEN stock worth over $153,355,168.

Thomas Neff FGEN stock SEC Form 4 insiders trading

Thomas has made over 122 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas sold 39,636 units of FGEN stock worth $1,757,064 on 21 August 2019.

The largest trade Thomas's ever made was exercising 80,000 units of FibroGen Inc stock on 20 December 2017 worth over $260,800. On average, Thomas trades about 30,710 units every 10 days since 2014. As of 21 August 2019 Thomas still owns at least 44,238 units of FibroGen Inc stock.

You can see the complete history of Thomas Neff stock trades at the bottom of the page.

What's Thomas Neff's mailing address?

Thomas's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.

Insiders trading at FibroGen Inc

Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff oraz Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.

What does FibroGen Inc do?

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.

Complete history of Thomas Neff stock trades at FibroGen Inc

FibroGen Inc executives and stock owners

FibroGen Inc executives and other stock owners filed with the SEC include:

• Kin-Hung Yu,
  Chief Medical Officer
• James Schoeneck,
  Chairman of the Board
• Elias Kouchakji,
  Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance
• Christine Chung,
  Senior Vice President, China Operations
• Pat Cotroneo,
  Chief Financial Officer
• Enrique A. Conterno,
  CEO & Director
• Dr. Elias Kouchakji,
  Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
• Pat Cotroneo,
  Exec. Advisor to CEO
• Suzanne Blaug,
  Independent Director
• Thane Wettig,
  Chief Commercial Officer
• Dr. Mark Eisner M.D., M.P.H.,
  Chief Medical Officer
• Thomas Kearns,
  Lead Independent Director
• Jeffrey Edwards,
  Independent Director
• Rory Riggs,
  Independent Director
• Gerald Lema,
  Independent Director
• Jeffrey Henderson,
  Independent Director
• Maykin Ho,
  Independent Director
• Kalevi Kurkijarvi,
  Independent Director
• Toshinari Tamura,
  Independent Director
• James A. Schoeneck,
  Chairman
• Benjamin Cravatt,
  Director
• Aoife Brennan,
  Director
• Thane Wettig,
  Chief Commercial Officer
• Percy Carter,
  Chief Scientific Officer
• Enrique Conterno,
  Chief Executive Officer, Director
• Dr. John J. Hunter Ph.D.,
  Chief Scientific Officer
• Dr. Michael J. Martinelli,
  Sr. VP of Technical Devel.
• Juan Graham,
  Chief Financial Officer
• Dr. Barry A. Berkowitz Ph.D.,
  Founder
• Jorma Routti,
  Director
• K Peony Yu,
  Chief Medical Officer
• Thomas B Neff,
  Chief Executive Officer
• Mark Eisner,
  EVP, Chief Medical Officer
• Julian N Stern,
  Director
• Frank H Md Valone,
  Chief Medical Officer
• Miguel Madero,
  Director
• Pharma Inc. Astellas,
  
• Juan Graham,
  CHIEF FINANCIAL OFFICER
• Deyaa Adib,
  Chief Medical Officer